| melanoma

Kimmtrak vs Tecentriq

Side-by-side clinical, coverage, and cost comparison for melanoma.

Deep comparison between: Kimmtrak vs Tecentriq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecentriq has a higher rate of injection site reactions vs Kimmtrak based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecentriq but not Kimmtrak, including UnitedHealthcare

Category

Kimmtrak

Tecentriq

At A Glance

RouteIV infusion

FrequencyWeekly

Classgp100/CD3 T cell engager

RouteIV infusion

FrequencyEvery 2-4 weeks

ClassPD-L1 antagonist

Indications

melanoma

Non-Small Cell Lung Carcinoma
Small cell carcinoma of lung
Liver carcinoma
Melanoma
Alveolar Soft Part Sarcoma

Dosing

Melanoma 20 mcg IV on Day 1, 30 mcg IV on Day 8, 68 mcg IV on Day 15, then 68 mcg IV once weekly thereafter; administer by intravenous infusion over 15-20 minutes.

Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.

Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.

Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.

Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.

Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.

Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.

Contraindications

—

Drug Interactions

26View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=30%) Cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, vomiting

Serious Cytokine release syndrome, skin reactions, elevated liver enzymes, rashes, pyrexia, hypotension

Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).

Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.

Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.

Pharmacology

Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed TCR CD3 T cell engager; it binds to gp100 peptide on HLA-A*02:01-positive uveal melanoma cells and activates polyclonal T cells to release inflammatory cytokines and cytolytic proteins, resulting in direct lysis of uveal melanoma tumor cells.

Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Kimmtrak